Is apixaban (Elliquis) indicated for valvular atrial fibrillation?

No, Eliquis (apixaban) is NOT indicated for valvular atrial fibrillation

Apixaban is FDA-approved and guideline-recommended exclusively for NONvalvular atrial fibrillation, not valvular AF. The FDA label explicitly states that Eliquis is indicated "to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation" 1. This distinction is critical and non-negotiable.

Understanding "Valvular" vs "Nonvalvular" AF

The term "valvular AF" traditionally refers to atrial fibrillation in patients with:

• Mechanical prosthetic heart valves (any position)
• Moderate-to-severe mitral stenosis (rheumatic or other etiology)

For these specific conditions, warfarin remains the only recommended anticoagulant 2. Guidelines explicitly state that for patients with mechanical heart valves, warfarin with target INR 2.0-3.0 or 2.5-3.5 (depending on valve type and position) is required 2.

The Nuance: Other Valvular Heart Disease

Here's where clinical practice has evolved: Patients with AF and other types of valvular heart disease (not mechanical valves or moderate-to-severe mitral stenosis) were actually included in the ARISTOTLE trial that established apixaban's efficacy. Specifically:

• 26.4% of ARISTOTLE trial patients had moderate or severe valvular heart disease 3
• This included patients with mitral regurgitation, aortic regurgitation, aortic stenosis, bioprosthetic valves, and prior valve repair
• Apixaban showed consistent efficacy and safety compared to warfarin in these subgroups 4, 5, 3

Therefore, apixaban can be used in AF patients with:

• Mitral regurgitation (any severity)
• Aortic regurgitation (any severity)
• Aortic stenosis (any severity)
• Bioprosthetic heart valves (after initial post-operative period)
• Prior native valve repair

Absolute Contraindications for Apixaban

Do NOT use apixaban in:

1. Mechanical prosthetic heart valves - The RE-ALIGN trial with dabigatran showed increased thromboembolic and bleeding events with DOACs in this population, leading to a class effect contraindication 2
2. Moderate-to-severe mitral stenosis - These patients were excluded from all DOAC trials 6, 2

Clinical Algorithm

When evaluating a patient with AF and valvular disease:

1. First, identify if they have mechanical valves or moderate-to-severe mitral stenosis

   • If YES → Use warfarin (INR 2.0-3.0 or 2.5-3.5 based on valve type)
   • If NO → Proceed to step 2

2. Assess for other valvular heart disease (MR, AR, AS, bioprosthetic valves, valve repair)

   • These patients can receive apixaban using standard nonvalvular AF dosing criteria 2
   • Dose: 5 mg twice daily, or 2.5 mg twice daily if ≥2 of: age ≥80 years, weight ≤60 kg, serum creatinine ≥1.5 mg/dL 6, 2

3. Calculate CHA₂DS₂-VASc score to determine need for anticoagulation

   • Score ≥2: Anticoagulation recommended (Class I) 2
   • Score 1: Consider anticoagulation (Class IIb) 2
   • Score 0: Reasonable to omit anticoagulation (Class IIa) 2

Common Pitfall

The most critical error is using "valvular AF" terminology loosely. Many clinicians incorrectly assume any patient with any valve disease has "valvular AF" and therefore cannot receive DOACs. This is wrong. The modern interpretation, supported by the 2014 and 2019 AHA/ACC/HRS guidelines, is that only mechanical valves and moderate-to-severe mitral stenosis constitute true contraindications to DOACs 2, 7.

Evidence Quality

The evidence supporting apixaban use in patients with valvular disease (excluding mechanical valves and significant mitral stenosis) comes from:

• ARISTOTLE trial subgroup analyses showing consistent benefit across valve disease subtypes 4, 5, 3
• Real-world observational data demonstrating safety and efficacy 8, 9
• Updated 2019 AHA/ACC/HRS guidelines that clarify the narrow definition of "valvular AF" 7

Bottom line: Use the term "nonvalvular AF" for FDA labeling purposes, but understand that most valvular heart disease (except mechanical valves and moderate-to-severe mitral stenosis) does not preclude apixaban use in clinical practice.